The reiteration of an Outperform rating and the maintenance of a $26 price target by a reputable analyst like Laura Chico from Wedbush suggests a strong vote of confidence in Edgewise Therapeutics. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in EWTX's stock price, reflecting the analyst's positive outlook.